Cargando…
Clinical use of biologics in vasculitis syndromes
Vasculitis syndromes are relative rare conditions but can cause significant mortality and morbidity if not treated adequately. Recent advances in immunosuppressant therapy have radically changed the course of these diseases. However, the standard therapy is not always well tolerated by patients, and...
Autor principal: | Paroli, Marino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484501/ https://www.ncbi.nlm.nih.gov/pubmed/23118526 http://dx.doi.org/10.2147/BTT.S37537 |
Ejemplares similares
-
New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond
por: Paroli, Marino, et al.
Publicado: (2023) -
Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis
por: Paroli, Marino, et al.
Publicado: (2023) -
Tubulointerstitial Nephritis and Uveitis Syndrome (TINU): A Case Series in a Tertiary Care Uveitis Setting
por: Paroli, Maria Pia, et al.
Publicado: (2022) -
When Autoantibodies Are Missing: The Challenge of Seronegative Rheumatoid Arthritis
por: Paroli, Marino, et al.
Publicado: (2023) -
Management Strategies of Juvenile Idiopathic Arthritis-Associated Chronic Anterior Uveitis: Current Perspectives
por: Paroli, Maria Pia, et al.
Publicado: (2022)